Theravance Biopharma Beheer
Beheer criteriumcontroles 3/4
De CEO Theravance Biopharma is Rick Winningham, benoemd in Jun2014, heeft een ambtstermijn van 10.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.32M, bestaande uit 24.3% salaris en 75.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.93% van de aandelen van het bedrijf, ter waarde $ 15.88M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 6.8 jaar.
Belangrijke informatie
Rick Winningham
Algemeen directeur
US$4.3m
Totale compensatie
| Percentage CEO-salaris | 24.3% |
| Dienstverband CEO | 10.4yrs |
| Eigendom CEO | 3.9% |
| Management gemiddelde ambtstermijn | 2.4yrs |
| Gemiddelde ambtstermijn bestuur | 6.8yrs |
Recente managementupdates
Recent updates
We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow
Jul 16
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now
May 02Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S
Feb 05Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts
Nov 11Theravance to purchase $95M of ordinary shares
Sep 28Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade
Sep 21Theravance Biopharma announces $250M capital return program
Sep 19Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M
Aug 04Theravance: All-Round Failure
Mar 10Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%
Aug 09Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study
Jun 21Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year
May 09Theravance Biopharma EPS misses by $0.16, misses on revenue
May 04Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$46m |
| Mar 31 2024 | n/a | n/a | -US$45m |
| Dec 31 2023 | US$4m | US$1m | -US$55m |
| Sep 30 2023 | n/a | n/a | -US$61m |
| Jun 30 2023 | n/a | n/a | -US$68m |
| Mar 31 2023 | n/a | n/a | -US$75m |
| Dec 31 2022 | US$6m | US$1m | -US$93m |
| Sep 30 2022 | n/a | n/a | -US$136m |
| Jun 30 2022 | n/a | n/a | -US$196m |
| Mar 31 2022 | n/a | n/a | -US$226m |
| Dec 31 2021 | US$4m | US$1m | -US$265m |
| Sep 30 2021 | n/a | n/a | -US$266m |
| Jun 30 2021 | n/a | n/a | -US$264m |
| Mar 31 2021 | n/a | n/a | -US$275m |
| Dec 31 2020 | US$7m | US$1m | -US$295m |
| Sep 30 2020 | n/a | n/a | -US$285m |
| Jun 30 2020 | n/a | n/a | -US$270m |
| Mar 31 2020 | n/a | n/a | -US$247m |
| Dec 31 2019 | US$6m | US$984k | -US$236m |
| Sep 30 2019 | n/a | n/a | -US$221m |
| Jun 30 2019 | n/a | n/a | -US$222m |
| Mar 31 2019 | n/a | n/a | -US$223m |
| Dec 31 2018 | US$3m | US$957k | -US$216m |
| Sep 30 2018 | n/a | n/a | -US$252m |
| Jun 30 2018 | n/a | n/a | -US$260m |
| Mar 31 2018 | n/a | n/a | -US$285m |
| Dec 31 2017 | US$2m | US$933k | -US$285m |
Compensatie versus markt: De totale vergoeding ($USD 4.32M ) Rick } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).
Compensatie versus inkomsten: De vergoeding van Rick is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Rick Winningham (64 yo)
10.4yrs
Tenure
US$4,318,531
Compensatie
Mr. Rick E. Winningham, M.B.A., served as Chairman of Retrotope Inc. since February 2021 until January 2022. He serves as Director at Rivus Pharmaceuticals, Inc. since 2024. He has been Lead Independent Di...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 10.4yrs | US$4.32m | 3.93% $ 15.9m | |
| Senior VP & CFO | 1.8yrs | US$1.39m | 0.66% $ 2.7m | |
| Senior VP of IT&I and Chief Information Officer | no data | geen gegevens | geen gegevens | |
| Vice President of Corporate Communications & Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior VP | 2.4yrs | geen gegevens | 0.70% $ 2.8m | |
| Chief Business Officer and Senior VP of Commercial & Medical Affairs | 2.9yrs | US$942.81k | 0.67% $ 2.7m | |
| Senior VP & Chief Strategy Officer | 2.2yrs | geen gegevens | geen gegevens | |
| SVP of Dev. | no data | geen gegevens | 0.33% $ 1.3m |
2.4yrs
Gemiddelde duur
54.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TBPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 11.3yrs | US$4.32m | 3.93% $ 15.9m | |
| Independent Director | 10.4yrs | US$205.14k | 0.14% $ 579.0k | |
| Independent Director | 4.3yrs | US$207.68k | 0.097% $ 392.1k | |
| Lead Independent Director | 10.4yrs | US$211.73k | 0.16% $ 666.2k | |
| Independent Director | 1.6yrs | US$43.10k | geen gegevens | |
| Independent Director | 9.1yrs | US$195.80k | 0.13% $ 525.6k | |
| Independent Director | 1.8yrs | US$346.47k | 0.064% $ 260.4k | |
| Independent Director | 6.8yrs | US$197.68k | 0.13% $ 532.0k | |
| Independent Director | less than a year | US$168.36k | 0.046% $ 184.5k |
6.8yrs
Gemiddelde duur
64.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TBPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).